PD-1 inhibition in metastatic dMMR/MSI-H colorectal cancer
-
Published:2017-09
Issue:9
Volume:18
Page:1141-1142
-
ISSN:1470-2045
-
Container-title:The Lancet Oncology
-
language:en
-
Short-container-title:The Lancet Oncology
Author:
Sclafani Francesco
Reference9 articles.
1. PD-1 blockade in tumors with mismatch-repair deficiency;Le;N Engl J Med,2015
2. Nivolumab in patients with metastatic DNA mismatch repair deficient/microsatellite instability-high colorectal cancer (CheckMate 142): results of an open-label, multicentre, phase 2 study;Overman;Lancet Oncol,2017
3. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma;Hugo;Cell,2016
4. Mutations associated with acquired resistance to PD-1 blockade in melanoma;Zaretsky;N Engl J Med,2016
5. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study;Domingo;Lancet Gastroenterol Hepatol,2016
Cited by
32 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献